Registration now open for veterinary professionals in Asia and Australia to access the latest insights in geroscience and nutritional strategies for aging companions

OVERLAND PARK, Kan., Oct. 23, 2025 /PRNewswire/ — Hill’s Pet Nutrition (Hill’s), a global leader in science-led nutrition, today announced the 2025 Hill’s Global Symposium, focusing on specialized care for aging pets. The Symposium is one of the largest free global education opportunities available for veterinary professionals worldwide. 

Registration is now open for the event, titled “Strong Science, Long Lives,” which builds on Hill’s foundation of research on senior pet health. Attendees can register for the livestream through Hill’s Veterinary Academy platform. Virtual registration also provides on-demand access to all sessions after the live event concludes. Simulated live streaming dates by region are as follows:

• Australia/New Zealand: October 29-30
• South Korea, Thailand, Taiwan and Japan: November 6-7

To register for Hill’s Global Symposium, visit your country’s registration link below:

• Australia
• New Zealand
• Japan
• Singapore
• South Korea
• Taiwan
• Thailand
• United Arab Emirates

Hill’s Global Symposium provides a forum for leading experts from across the globe to discuss the power of nutrition and its place at the forefront of healthcare for aging pets. Attendees will gain innovative insights and practical applications to guide clinical decision-making, covering topics such as veterinary geroscience, cognitive dysfunction syndrome, mobility issues and clinical approaches to senior patients with multiple comorbidities, among other areas.

“The ‘Strong Science, Long Lives’ theme of this year’s Hill’s Global Symposium perfectly encapsulates our mission,” said Dr. Jolle Kirpensteijn, chief veterinary officer of Hill’s Pet Nutrition. “We believe that by delving deep into the scientific study of aging (geroscience) and applying cutting-edge nutritional strategies, we can significantly improve the quality and longevity of life for aging pets.”

Attendees will hear from more than 18 renowned experts, including Hill’s scientists and nutritionists. Speakers will delve into the aging process as it relates to pets and their guardians – from cognitive dysfunction and concurrent conditions to hospice care and client communication. Among the distinguished presenters are:

• Keynote speaker Nicole Ehrhart, VMD, MS, DACVS, ACVS Founding Fellow, Surgical Oncology, director of Columbine Health Systems Center for Health Aging and professor at Colorado State University, who will open the Symposium with a presentation on understanding the aging process through Great Danes and the science of longevity.
• Keynote speaker Natasha Olby, Vet MB, PhD, MRCVS, DACVIM (Neurology), professor of veterinary neurology and neurosurgery at North Carolina State University, who will speak on mobility loss in senior dogs.
• Katie Tolbert, DVM, PhD, DACVIM (SAIM, SA Nutrition), clinical associate professor in small animal and comparative gastroenterology at Texas A&M University, who will explore frailty and comorbidities in geriatric small animal patients.
• Allison McGrath, M.S., scientist at Hill’s with Global Clinical Nutrition and Claims, and Lisa Restine, DVM, DABVP (Feline), feline professional veterinary affairs manager at Hill’s, who together will explore the vital role of nutrition in feline cognition.

“The Hill’s Global Symposium stands as a testament to our unwavering commitment to advancing the veterinary profession,” said Dr. Jill Zigomanis, Director of Professional Veterinary Affairs, Hill’s Pet Nutrition Asia. “As pets live longer, our understanding of their unique needs in their senior years must evolve. We are bringing together the brightest minds to share groundbreaking research and  practical strategies to help veterinary professionals effectively manage and promote healthy aging for pets.”

Hill’s Pet Nutrition is committed to supporting the health of senior pets through innovative therapeutic and wellness-based nutrition. The Symposium will highlight Hill’s products, providing veterinarians with a complete suite of pet foods to help manage senior patient cases.

To learn more about the 2025 Hill’s Global Symposium, including the detailed agenda, full speaker roster, and registration information for the free virtual event, please visit Hill’s Veterinary Academy via country links above.

About Hill’s Pet Nutrition

Founded more than 75 years ago, Hill’s Pet Nutrition has been committed to providing pets with the best nutrition through extensive research and a scientific understanding of their specific needs. Their team of nearly 200 veterinarians, PhD nutritionists, and food scientists constantly strive to develop innovative solutions for pet health. Hill’s offers a full line of products, including their Prescription Diet therapeutic nutrition and Science Diet wellness products, which are available at veterinary clinics and pet specialty retailers worldwide. For more information about their products and nutritional philosophy, please visit HillsPet.com.

Media Contact: Emma Honn, emma.honn@vml.com

ABU DHABI, UAE, Oct. 23, 2025 /PRNewswire/ — The Natural History Museum Abu Dhabi will open to the public on 22 November in Saadiyat Cultural District, marking a significant cultural milestone for the emirate. As the largest museum of its kind in the region, it represents a new global destination for science, nature, and education, inviting visitors to explore the story of life on our planet and engage in conversations about its future.

Natural History Museum Abu Dhabi to Open in Saadiyat Cultural District on 22 November

The 35,000-square-metre museum is an exciting addition to the UAE’s evolving cultural landscape. It takes visitors on an immersive journey through 13.8 billion years of natural history – from the Big Bang and the formation of our solar system to the evolution of life, including the rise and fall of dinosaurs and the extraordinary biodiversity of our planet.

Among the highlights of the museum are three travellers from deep time. One is the famed specimen affectionately known as Stan, a nearly complete skeleton of a mighty Tyrannosaurus rex, an apex predator which ruled the Earth 67 million years ago. It is joined by the largest animal ever known, represented by a magnificent, 25-metre female blue whale specimen, offering extraordinary insight into evolution, marine biodiversity, and the planet’s ongoing story of life. Completing the trio is the Murchison Meteorite – an artefact that witnessed the formation of our planet and contains 7-billion-year-old grains formed even before our Solar System.

H.E. Mohamed Khalifa Al Mubarak, Chairman of the Department of Culture and Tourism – Abu Dhabi, said: “The opening of the Natural History Museum Abu Dhabi marks a major milestone in our journey to shape the emirate’s cultural landscape. The museum offers an immersive look at the story of life on Earth, framed for the first time through an Arabian lens, with the fauna, flora, and geological history of the region forming a prominent part of the visitor journey. The museum’s research and educational institution supports scientific knowledge and undertakes innovative scientific studies in zoology, palaeontology, marine biology, molecular research and earth sciences. By fostering engagement with the natural sciences, the Natural History Museum Abu Dhabi inspires future generations and contributes to a more sustainable future.”

Across the galleries, the natural history of the Arabian Peninsula forms a central part of the museum’s narrative, highlighting the region’s unique contribution to Earth’s story. Among the most remarkable discoveries found in Abu Dhabi is an extinct species of elephant known as Stegotetrabelodon emiratus. This ancient member of the Elephantidae family was distinguished by tusks in both its upper and lower jaws — a rare trait unseen in modern elephants.

The museum joins a community of institutions including Louvre Abu Dhabi, teamLab Phenomena Abu Dhabi, and the upcoming Zayed National Museum and Guggenheim Abu Dhabi.

About the Natural History Museum Abu Dhabi

The Natural History Museum Abu Dhabi is established with the ambition to become a trusted research museum with world-class collections, engaging visitor experiences, strong educational programmes, accessible community science, and a commitment to sustainable change through national and global collaboration. Located in the Saadiyat Cultural District, Abu Dhabi, the museum tells the epic story of life on earth through an Arabian lens. The 35,000 sqm museum build by renowned architects Mecanoo, offering an immersive journey through time, inviting visitors to explore the story of life on Earth from the beginning of the universe to the possibilities and responsibilities of our planetary future.

From rare meteorites and iconic dinosaur fossils to the lost world of Abu Dhabi and life on earth today, the Natural History Museum Abu Dhabi connects past, present, and future through its globally significant collections and the powerful stories they reveal. Interactive exhibits, immersive experiences, and community-science programmes make the museum an ever-changing space of curiosity and connection for families, students, researchers and lifelong learners.

More than a museum, Natural History Museum Abu Dhabi is a global hub for cutting-edge research. State-of-the-art laboratories will advance studies in palaeontology, earth sciences, biodiversity research, conservation and community science, fostering international collaboration and knowledge that supports a healthier planet. Guided by the UAE’s commitment to science, sustainability and global dialogue, the museum inspires visitors of every age to become advocates for nature and stewards of our shared future.

MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (¹⁵³Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for treating pain associated with bone metastasis.

TLX090 is designed to deliver targeted radiation to bone tumors while minimizing damage to surrounding healthy tissues. SOLACE (Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage bone pain) is an open-label Phase 1 clinical trial enrolling up to 33 patients with advanced cancer that has metastasized to the bony skeleton^[1]. The trial is designed to evaluate the pharmacokinetics, dosimetry, safety, and pain palliation of TLX090, a next-generation radiopharmaceutical candidate optimized for improved safety profile and efficacy. Data from SOLACE aims to establish clinical comparability to legacy ¹⁵³Sm treatments, which in turn is expected to support a streamlined registration pathway as an analgesic, paving the way for a much-needed, non-opioid solution for patients living with bone pain in the late stages of advanced cancer.

Pain from osteoblastic bone metastases is one of the most common and debilitating symptoms in advanced cancer, with approximately 400,000 new cases diagnosed^[2] each year. Up to 90% of patients with metastatic prostate cancer^[3],[4] are affected, contributing to reduced quality of life and mental health. Despite the availability of opioids and external beam radiation therapy (EBRT), many patients remain under-treated — underscoring a critical unmet need for a systemic, targeted, and non-opioid solution that can deliver durable relief across multiple cancer types.

The current standard of care can provide only partial relief^[5] and comes with significant drawbacks. Opioids are associated with sedation, constipation, dependency, and regulatory scrutiny, especially in the post-Purdue litigation era^[6]. Health systems face high costs and administrative burdens in managing chronic opioid use, including monitoring, compliance, and risk mitigation. EBRT is often ineffective^[7] as it is localized, logistically intensive, and not suitable for patients with multifocal or diffuse bone pain.

By comparison, TLX090 offers the potential for a cost-effective, systemic, targeted and non-opioid alternative that may treat pain, reduce reliance on chronic pain medications and improve quality-of-life through a single administration that could deliver up to 3-4 months of pain relief, with the ability to provide repeat doses. An earlier study^[8] demonstrated a favorable early safety profile and encouraging efficacy signal, while the potential to treat pain associated with multiple cancer types expands Telix’s clinical reach into disease areas such as prostate, and breast cancer. The novel cold-kit formulation and pharmacy-based distribution of TLX090 may also aid in overcoming barriers to treatment due to cost and supply chain limitations associated with legacy products.

Julio A. Peguero MD, Medical Director of Research, Oncology Consultants, Houston (TX), said, “We are proud to support the SOLACE trial, which brings new hope to patients living with metastatic bone pain. Existing treatments often fall short—whether through limited effectiveness, incomplete pain relief, or burdensome side effects. TLX090 offers the potential for a better tolerated and more effective approach to pain management, with the goal of meaningfully improving patients’ quality of life.”

David N. Cade MD, Group Chief Medical Officer, Telix, said, “Even with the introduction of new treatments, including targeted radiation therapy, most metastatic cancer patients will eventually progress and need treatment for bone pain. TLX090 has the potential to bridge cancer treatment and quality-of-life care by offering a single-dose, systemic option for these patients addressing the significant unmet need across multiple cancer types. This presents a major clinical opportunity, aligned with our commitment to prostate cancer, and a potential commercial entry point into the therapeutic market. Thank you to Oncology Consultants in Houston for partnering with us on this important clinical trial.”

TLX090 has not received a marketing authorization in any jurisdiction.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)  

Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Media Contact

Eliza Schleifstein
Eliza@schleifsteinpr.com

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

HONG KONG, Oct. 22, 2025 /PRNewswire/ — JoJo Ventures has officially launched JifChat, an intuitive AI design agent built to eliminate the frustrations of text-based prompting. Designed for sellers, marketers, brands, and creators, JifChat transforms the way visual content is created — empowering users to show, not tell, what they want.

For years, creators have struggled to translate visual ideas into words — wasting hours on trial and error. JifChat replaces that struggle with visual-first, no-type workflows that deliver professional-quality assets in seconds.

Built in Hong Kong, for Asian Creators

JifChat is proudly built by a Hong Kong team — for Asian creators.

The platform addresses one of the biggest cultural gaps in today’s AI image generation: representation.

In JifChat, every creative detail — from people to streets, food, and architecture — reflects your daily life and culture.

When you type “a girl”, you’ll see an Asian face. When you add Chinese text to your image, the output will display it correctly — no more broken characters or gibberish. You can even chat naturally in Cantonese or your most familiar language, without being forced to prompt in precise English.

Workflow That Works Like Magic

At the heart of JifChat is its revolutionary Workflow system — enabling users to turn simple inputs into polished, ready-to-use visuals in seconds. From transforming a basic product shot into a dynamic advertisement to generating multiple model poses from a single image, JifChat makes professional-grade creation effortless.

Powerful Features for Visual Control

Beyond Workflows, JifChat offers powerful creative controls: over 20 Styles, direct In-Chat Image Interaction, realistic Mockups, and Advanced Model Control for aspect ratios and reference precision.

Empowering Brands and Businesses

JifChat is positioned to become an essential creative partner for businesses that demand both speed and quality. Whether it’s an e-commerce seller designing product visuals, a brand manager preparing campaign assets, or a marketer producing social media creatives, JifChat brings professional-grade output within reach — instantly.

By combining guided automation with human-like visual intelligence, JifChat bridges the gap between AI generation and real-world design needs.

Availability

JifChat is now available at www.jif.dev, with free trials open to all creators. Users can also join the official Discord community to share feedback and connect directly with the development team.

About JifChat

JifChat is an AI design agent built by JoJo Ventures, the organizer behind GENAI Summit and a pioneer in creative AI innovation in Hong Kong.

Originally developed as an internal tool for JoJo Ventures’ own creative projects, JifChat evolved into a full-featured design agent that combines automation, precision, and cultural authenticity.

Today, it empowers creators and businesses across Asia to turn ideas into visuals — instantly, intuitively, and with local identity in mind.

NEWPORT BEACH, Calif., Oct. 23, 2025 /PRNewswire/ — MindHYVE.ai™, Inc., a pioneering force in agentic AI and autonomous intelligence systems, announced that it has mandated The Dawn Directive training program for all employees across various geographic locations. This strategic move cements MindHYVE’s role as both a market leader in AGI innovation and an employer dedicated to equipping its teams with the most critical skills of the AI economy.

The Dawn Directive—authored entirely by MindHYVE’s own neuro-symbolic AGI reasoning model—is a first of its kind, 18-course educational program published by California Institute of Artificial Intelligence (CIAI). Delivered through the ArthurAI™ Virtual Learning Platform, the curriculum covers AI literacy, prompt engineering, workflow orchestration, ethical AI, and future-skills designed to accelerate workforce readiness.

“AI fluency is no longer optional—it’s a baseline requirement,” said Bill Faruki, Founder and CEO of MindHYVE.ai™. “By mandating The Dawn Directive, we are ensuring every MindHYVE employee is not just using AI but mastering how to direct it—through prompt engineering, orchestration, and responsible application. This gives us an edge internally, while setting the bar for what AI-powered organizations should look like externally.”

The rollout of The Dawn Directive across MindHYVE’s offices in the U.S., Africa and Pakistan represents a transformational milestone in the company’s talent and innovation strategy. Key benefits for employees include:

• Prompt Engineering Expertise — developing mastery in crafting precise, context-aware prompts that unlock maximum AI performance.
• Applied AI Fluency — hands-on skills in building workflows, orchestrating tools, and delivering explainable, scalable outputs.
• Ethics & Compliance Readiness — embedding global AI governance standards (GDPR, HIPAA, SEC compliance) into everyday work.
• Future-Proof Resilience — building adaptability, meta-skills, and leadership to thrive alongside autonomous systems.

MindHYVE’s decision positions the company as an industry benchmark for AI workforce development. As enterprises worldwide face the AI fluency gap, MindHYVE.ai™ is demonstrating how to close it—by making adaptive, AI-authored education mandatory rather than optional.

About MindHYVE.ai™

MindHYVE.ai™ is redefining the boundaries of intelligence by engineering autonomous systems and deploying domain-specific AGI agents across real-world sectors. Powered by the Ava-Fusion™ large reasoning model and architected for agent coordination, swarm intelligence, and adaptive autonomy, MindHYVE’s technology stack is revolutionizing law, medicine, finance, education, and governance.

With operations in North America, Asia, and in Africa, MindHYVE.ai™ is on a mission to democratize access to transformative intelligence and architect the infrastructure for post-scarcity economies. Backed by HYVE Labs, the company continues to shape the future of agentic systems on a global scale.

Website: www.mindhyve.ai | Email: hello@mindhyve.io | Contact: +1 (949) 200-8668

Media Contact:

Marc Ortiz
Email: marc.ortiz@mindhyve.io

DUBLIN and STAMFORD, Conn. and NEW YORK, Oct. 23, 2025 /PRNewswire/ — Phoenix Aviation Capital (“Phoenix” or “the Company”), a full-service aircraft lessor managed by AIP Capital (“AIP”), an alternative investment manager focused on opportunities in asset-based finance and a portfolio company of funds advised or controlled by affiliates of BC Partners Advisors L.P., announced a $250 million upsize to its $300 million senior secured credit facility (“the facility”), bringing total commitments to the facility to $550 million.

HSBC, Truist, Fifth Third Bank, Crédit Agricole, BNP Paribas and Bayern LB participated in this upsize to the facility. Royal Bank of Canada (“RBC”) acted as Structuring Agent with RBC, Citibank and Morgan Stanley acting as Joint Lead Arrangers. Since the beginning of 2025, Phoenix has raised over $2 billion in bank and institutional capital to support its growth strategy.

“This expanded participation in the facility represents further confidence in the business among Phoenix’s lender group,” said Jared Ailstock, Managing Partner at AIP. “We are grateful for the support from the bank group as we continue to execute on Phoenix’s growth strategy.”

“Welcoming new lenders demonstrates the support Phoenix and AIP have in the aviation bank market,” said Patrick Schafer, Partner at BC Partners and board member of Phoenix. “The facility will provide Phoenix with additional capacity and flexibility to support the Company’s global airline customers.”

Vedder Price served as transaction counsel and PwC acted as tax advisor to Phoenix and AIP. McCann Fitzgerald also acted in capacity as Irish counsel to Phoenix and AIP. Clifford Chance served as transaction counsel to the lenders.

About AIP Capital
AIP Capital (AIP) is a global alternative investment manager focused on opportunities in asset-based finance including aviation and equipment finance. AIP, together with its affiliates, manages approximately $4 billion of assets on behalf of a diversified global investor base. The AIP team is comprised of more than 50 experienced professionals across AIP’s offices in Stamford, New York City, Dublin, and Singapore. For more information about AIP Capital or to speak with company executives, please contact investor.relations@aipcapital.com.

About BC Partners & BC Partners Credit
BC Partners is a leading international investment firm in private equity, private debt, and real estate strategies. BC Partners Credit was launched in February 2017, with a focus on identifying attractive credit opportunities in any market environment, often in complex market segments. The platform leverages the broader firm’s deep industry and operating resources to provide flexible financing solutions to middle-market companies across Business Services, Industrials, Healthcare and other select sectors. For further information, visit www.bcpartners.com/credit-strategy.

Media Contacts

AIP Capital Geoffrey Bayers
investor.relations@aipcapital.com

BC Partners
Luke Charalambous
Luke.Charalambous@BCPartners.com
+44 7775 180 721